Next-generation naloxone for the synthetic opioid era
Rapid rescue. Sustained protection.
THE INVESTMENT CASE IN THREE POINTS
Elysium Therapeutics develops medicines designed to perform safely and effectively in the real world—not just under controlled conditions. We intentionally engineer therapeutic profiles to preserve efficacy while addressing limitations revealed in patient care. Our lead programs aim to save lives from synthetic-opioid overdose, follow de-risked development pathways, and address large commercial markets—with potential government applications providing additional upside.
SAVE LIVES — Protection designed to outlast the threat.
DE-RISKED DEVELOPMENT — Established medicine. Fast onset and sustained protection shown preclinically. Lower cost, faster development path.
BIG MARKETS — $700M commercial rescue market—plus potential government demand.
SOOPR™ Rescue + SOOPR ES™
Elysium is developing next-generation naloxone for the synthetic opioid era. SOOPR Rescue is designed to combine rapid overdose reversal with sustained protection against recurrent respiratory depression. SOOPR ES extends that protection for high-risk and potential mass-casualty settings. Both are investigational and are not approved for commercial sale or procurement.